July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) tested in observational longitudinal study of patients with neovascular Age-related Macular Degeneration (Norwegian cohort).
Author Affiliations & Notes
  • Elma Jelin
    Ophthalmology, Oslo University Hospital, Oslo, Norway
    Institute of Clinical Medicin, University of Oslo, Oslo, Norway
  • Torbjørn Wisløff
    Norwegian Institute of Public Health, Oslo, Norway
    Institute of Health and Society, University of Oslo, Oslo, Norway
  • Morten C Moe
    Ophthalmology, Oslo University Hospital, Oslo, Norway
    Institute of Clinical Medicin, University of Oslo, Oslo, Norway
  • Turid Heiberg
    Regional Research Support, Oslo University Hospital, Oslo, Norway
    Østfold University College, Oslo, Norway
  • Footnotes
    Commercial Relationships   Elma Jelin, None; Torbjørn Wisløff, None; Morten Moe, investigator in an Alcon sponsored clinical trial (F), member of Bayer and Novartis advisory boards (C); Turid Heiberg, None
  • Footnotes
    Support  The Norwegian Nurses Organisation 15/0015 and the grant from Division of Head, Neck and Reconstructive Surgery at Oslo University Hospital
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 804. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elma Jelin, Torbjørn Wisløff, Morten C Moe, Turid Heiberg; Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) tested in observational longitudinal study of patients with neovascular Age-related Macular Degeneration (Norwegian cohort).. Invest. Ophthalmol. Vis. Sci. 2018;59(9):804.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To explore real-life treatment of neovascular Age-related Macular Degeneration (nAMD) using a Treat and extend (T/E) protocol with NEI-VFQ 25 and examine it`s psychometric properties in a Norwegian cohort.

Methods : Newly diagnosed nAMD patients responded to NEI-VFQ 25 at baseline (n=197), 3- (n=186) and 6 months (n=176) after initiating anti-VEGF intravitreal injections using a T/E protocol. Face validity was tested for relevance on NRS 0-10 (10=most relevant). Liner regression was performed between NEI-VFQ 25 and LogMar (best and treated eye) as well as other relevant variables and instruments measuring patient reported general and visual health. Reliability tests were performed by test-retest on a sub group of patients (n=30) at 6 months, one week apart using Intraclass Correlation Coefficient (ICC). Internal consistency was tested with Cronbach`s alpha for overall- and sub scores. Sensitivity to change was tested using NEI-VFQ 25 overall score (baseline to 3 months). Paired t-tests were performed including LogMar treated eye. Finally, standardized response mean (SRM) was calculated.

Results : Face validity of NEI-VFQ 25 at 3 months (n=84) was strong with mean (SD) of 7.8 (1,7). LogMar best/treated eye, Patients acceptable symptom state (PASS 5), and the generic health questionnaire EQ-5D were each significantly correlated to NEI-VFQ 25 overall score at baseline, 3- and 6 months (except for EQ-5D in 6 months). Significant correlation was found as well between number of injections with both LogMar treated eye and NEI-VFQ 25 overall score at 6 months. Test-retest showed high ICC value of 0.91 and Cronbach`s alpha of 0.83 for overall score, which shows that NEI-VFQ 25 has satisfactory reliability and internal consistency. Change from baseline to 3 months in NEI-VFQ 25 overall score was significant (p<0.001), which is coherent with change in LogMar treated eye. Finally, SRM showed a change of 0.33.

Conclusions : NEI-VFQ 25 shows valid and reliable psychometric properties, and can be used to monitor patients treated for nAMD using a T/E protocol.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Table: Internal consistency and test-retest of NEI-VFQ 25.

Table: Internal consistency and test-retest of NEI-VFQ 25.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×